Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Karimah Es Sabar also recently made the following trade(s):

• On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.03, for a total value of $1,667,397.05.

Capricor Therapeutics Price Performance

CAPR traded up $1.50 during trading hours on Thursday, hitting $31.62. 346,173 shares of the stock were exchanged, compared to its average volume of 1,371,751. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -14.08 and a beta of 0.48. The stock has a 50-day simple moving average of $27.04 and a 200-day simple moving average of $18.74. Capricor Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Sell-side analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its position in shares of Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after purchasing an additional 116,373 shares during the period. Geode Capital Management LLC grew its holdings in Capricor Therapeutics by 6.8% during the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock worth $9,565,000 after acquiring an additional 61,701 shares during the period. Legal & General Group Plc grew its holdings in Capricor Therapeutics by 8.4% during the second quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 3,205 shares during the period. Rhumbline Advisers raised its position in Capricor Therapeutics by 7.3% in the second quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock worth $531,000 after acquiring an additional 3,636 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Capricor Therapeutics in the 2nd quarter valued at about $796,000. Institutional investors own 21.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. UBS Group set a $50.00 price target on Capricor Therapeutics in a report on Monday, December 15th. Piper Sandler restated an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Wall Street Zen downgraded Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Finally, Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $46.09.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.